Compare Medpace Holdings Inc (MEDP) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Xpeng Inc - ADR — how do they compare? Medpace Holdings Inc trades at $533.39 (market cap $15.08B), while Xpeng Inc - ADR trades at $13.16 (market cap $12.96B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| MEDP | XPEV | |
|---|---|---|
Market Cap | $15.08B | $12.96B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $28.07 |
52-Week Low | $308.88 | $12.09 |
Enterprise Value | $14.55B | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPEV stock trades at $13.22, down 2.33% on the day, with a neutral technical outlook. The company reported revenue of $76.72 billion in 2025, but net losses persist, though the margin improved to -1.49%. Recent news highlights overseas expansion with the L03 SUV launch in Munich and progress in autonomous driving technology. Analyst consensus is bullish with a $17.00 price target, but cash flow volatility and competitive pressures remain concerns.
The outlook for XPEV hinges on execution of global expansion and new model launches to drive profitability. Investment opportunity lies in market share gains and technology leadership in EVs and AI, but risks include intense competition, reliance on Chinese market dynamics, and ongoing cash burn. The stock offers growth potential if the company can sustain revenue growth and narrow losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
